lampalizumab   Click here for help

GtoPdb Ligand ID: 8294

Synonyms: anti-factor D | FCFD4514S | RG7417
Compound class: Antibody
Comment: Lampalizumab is the Fab antigen binding domain of a humanized monoclonal antibody targeting complement factor D (CFD), the rate-limiting initiator of the alternative complement pathway (AP). The humanized antibody was produced based on a mouse monoclonal (MAb 166-32) [3,5].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Lampalizumab is being assessed in Phase 3 clinical trials as a potential treatment for geographic atrophy associated with age-related macular degeneration (AMD). See NCT02247479 and NCT02247531.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Preclinical and clinical evidence implicates CFD in AMD, with overactivation of AP believed to play a significant role in the progression of the disease [1]. Therefore, inhibition of the initiating activator of this pathway (CFD) would be expected to reduce disease symptoms, or at least slow progression [2].